česky english polski

About company


Myriad was formed in 1991 as one of the first genomic companies with a clear vision of elucidating the role genes play in human disease, and using this essential information to improve patient healthcare by the developing novel molecular diagnostic products.

Myriad scientists working with many collaborators from around the world have discovered many important disease-causing genes. A sample of Myriad’s discoveries include the:

  • BRCA1 and BRCA2 hereditary breast and ovarian cancer genes
  • p16 cell cycle control gene that increases the risk of developing a variety of cancers, notably melanoma
  • PTEN tumor suppressor gene that is involved in the development of many cancers, and
  • ELAC2 prostate cancer gene

In 1996, Myriad introduced the first molecular diagnostic test for a hereditary breast and ovarian cancer, BRACAnalysis® followed by eight additional innovative molecular diagnostic tests for breast, prostate, colon, pancreatic, ovarian, uterine cancers and melanoma.

In the field of hereditary cancer Myriad diagnosed more than 1 million patients, identified more than 16,000 unique mutations it´s the unquestioned industry leader in variant classification and reclassification. Myriad has built and maintains a proprietary database that is larger than any other, allowing to provide fast, accurate answers and to have the lowest Variant of Uncertain Significance rate in the world. The current BRCA1/BRCA2 VUS rate for testing performed by Myriad is 0,6%, respectively 1,6% for BRCA2. Other laboratories in Europe report VUS values ​​above 25%. The analytical sensitivity of Myriad´s tests reaches 99.98%.




to assess an individual´s risk for developing disease


to identify a patient´s likelihood of responding to a particular therapy to ensure optimal treatment decisions


to assess a patient´s risk of disease progression and recurrence, so that a physician knows how aggressively to treat the patient´s disease